奥拉帕尼
医学
卵巢癌
内科学
维持疗法
化疗
B组
肿瘤科
回顾性队列研究
单中心
无进展生存期
癌症
外科
聚ADP核糖聚合酶
生物化学
化学
聚合酶
基因
作者
Yafeng Dong,Yanbin Zhang,Ping Gong,Shi‐Bin Ren,Yubi Gan,Feiran Liu,Chao Wang,Xinguo Zhao,Renzi Liu,Wenpei Bai
出处
期刊:Ejso
[Elsevier]
日期:2024-02-01
卷期号:50 (2): 107950-107950
被引量:2
标识
DOI:10.1016/j.ejso.2024.107950
摘要
To evaluate the effect of secondary cytoreductive surgery (SeCRS) followed by platinum-based chemotherapy (PBC) and olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent epithelial ovarian cancer.This was a retrospective study of a prospective database. We collected information on 623 patients diagnosed with BRCA mutated recurrent epithelial ovarian cancer, all of whom underwent SeCRS followed by PBC in combination with or without olaparib. Overall survival and progression-free survival were measured to evaluate treatment effectiveness.Of the 623 patients recruited, 240 underwent SeCRS plus hyperthermic intraperitoneal chemotherapy followed by PBC and olaparib maintenance therapy (Group A), 248 underwent SeCRS followed by PBC and olaparib maintenance therapy (Group B), and 135 underwent SeCRS followed by PBC only upon recurrence (Group C). The median progression-free survival for Group A was significantly longer than that for Group B (32.5 vs. 24.2 months, P<0.001), and Group B was significantly longer than Group C (24.2 vs. 15.1 months, P<0.001). The median overall survival for Groups A was significantly longer than that for Group B (71.4 vs. 63.5 months, P<0.001), and Group B was significantly longer than Group C (63.5 vs. 47.5 months, P<0.001).This study suggested that SeCRS followed by PBC and olaparib maintenance therapy resulted in longer overall survival and progression-free survival than SeCRS followed by PBC only in patients with BRCA mutated recurrent ovarian cancer, especially in patients treated with SeCRS plus hyperthermic intraperitoneal chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI